Additionally, If the decreased ovarian reserve in BRCAm1 will be confirmed in future trials, the possible increased risk of gonadotoxicity in breast cancer patients carrying the BRCA1 pathogenic variant should be another issue to consider when counseling these patients. This evidence concerns the gene BRCA1 and breast cancer.